323 related articles for article (PubMed ID: 11964281)
1. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
Bollard CM; Rössig C; Calonge MJ; Huls MH; Wagner HJ; Massague J; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 May; 99(9):3179-87. PubMed ID: 11964281
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
Foster AE; Dotti G; Lu A; Khalil M; Brenner MK; Heslop HE; Rooney CM; Bollard CM
J Immunother; 2008 Jun; 31(5):500-5. PubMed ID: 18463534
[TBL] [Abstract][Full Text] [Related]
3. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
Lacuesta K; Buza E; Hauser H; Granville L; Pule M; Corboy G; Finegold M; Weiss H; Chen SY; Brenner MK; Heslop HE; Rooney CM; Bollard CM
J Immunother; 2006; 29(3):250-60. PubMed ID: 16699368
[TBL] [Abstract][Full Text] [Related]
4. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
Fanayan S; Firth SM; Butt AJ; Baxter RC
J Biol Chem; 2000 Dec; 275(50):39146-51. PubMed ID: 10993898
[TBL] [Abstract][Full Text] [Related]
6. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling.
Fanayan S; Firth SM; Baxter RC
J Biol Chem; 2002 Mar; 277(9):7255-61. PubMed ID: 11751851
[TBL] [Abstract][Full Text] [Related]
7. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
Bollard CM; Tripic T; Cruz CR; Dotti G; Gottschalk S; Torrano V; Dakhova O; Carrum G; Ramos CA; Liu H; Wu MF; Marcogliese AN; Barese C; Zu Y; Lee DY; O'Connor O; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2018 Apr; 36(11):1128-1139. PubMed ID: 29315015
[TBL] [Abstract][Full Text] [Related]
10. Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes.
Papadakis KA; Krempski J; Reiter J; Svingen P; Xiong Y; Sarmento OF; Huseby A; Johnson AJ; Lomberk GA; Urrutia RA; Faubion WA
Am J Physiol Cell Physiol; 2015 Mar; 308(5):C362-71. PubMed ID: 25472963
[TBL] [Abstract][Full Text] [Related]
11. Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines.
Inman GJ; Allday MJ
J Gen Virol; 2000 Jun; 81(Pt 6):1567-78. PubMed ID: 10811940
[TBL] [Abstract][Full Text] [Related]
12. Resistance to TGF-beta1-mediated growth inhibition correlates with sustained Smad2 phosphorylation in primary murine splenocytes.
Feldmann K; Sebald W; Knaus P
Eur J Immunol; 2002 May; 32(5):1393-402. PubMed ID: 11981827
[TBL] [Abstract][Full Text] [Related]
13. Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours.
Paiva CE; Drigo SA; Rosa FE; Moraes Neto FA; Caldeira JRF; Soares FA; Domingues MAC; Rogatto SR
Ann Oncol; 2010 Apr; 21(4):734-740. PubMed ID: 19914962
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
[TBL] [Abstract][Full Text] [Related]
15. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
[TBL] [Abstract][Full Text] [Related]
16. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
[TBL] [Abstract][Full Text] [Related]
17. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response.
Tiemessen MM; Kunzmann S; Schmidt-Weber CB; Garssen J; Bruijnzeel-Koomen CA; Knol EF; van Hoffen E
Int Immunol; 2003 Dec; 15(12):1495-504. PubMed ID: 14645158
[TBL] [Abstract][Full Text] [Related]
19. Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells.
Heldin NE; Bergström D; Hermansson A; Bergenstråhle A; Nakao A; Westermark B; ten Dijke P
Mol Cell Endocrinol; 1999 Jul; 153(1-2):79-90. PubMed ID: 10459856
[TBL] [Abstract][Full Text] [Related]
20. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
